GlassScriptPhysician profile
Jeffrey A Johnson
NPI 1750360202
$245.56
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $48.48 · 2022: $66.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $128.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $43.27 | 2019 | |
| Amgen INC. | $15.89 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.33 | 2019 | |
| Pfizer INC. | $13.19 | 2020 | |
| Grifols USA, LLC | $13.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.81 | 2019 | |
| Dynavax Technologies Corporation | $6.88 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.